Trial reportJournal of endocrinological investigation2009
Visfatin plasma concentrations in patients with hyperthyroidism and hypothyroidism before and after control of thyroid function.
Trial report in Journal of endocrinological investigation, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Non-alcoholic fatty liver disease and thyroid dysfunction: a systematic review.World journal of gastroenterology · 2014Pooled it
- Levothyroxine monotherapy has limited effects on body composition in clinical and subclinical hypothyroidism: a systematic review and meta-analysis.Reviews in endocrine & metabolic disorders · 2026Review
- Adipocytokine Profiles in Type 2 Diabetes Mellitus and Autoimmune Thyroid Disease: Associations With Metabolic and Hormonal Parameters.Physiological research · 2026Article
- Relationship Between Thyroid Dysfunction and Ovarian Cancer.Biomolecules · 2025Review
- Type 2 Diabetes Mellitus Coincident with Clinical and Subclinical Thyroid Dysfunctions Results in Dysregulation of Circulating Chemerin, Resistin and Visfatin.Biomedicines · 2023Article
- The Association Between Three Adipocytokines (Adiponectin, Resistin and Visfatin) And Thyroid Status in Patients With Type 2 Diabetes Mellitus and Autoimmune Thyroiditis.Physiological research · 2021Article
- Article
- Effect of restoration of euthyroidism on visfatin concentrations and body composition in women.Endocrine connections · 2021Article
- Role of Nampt overexpression in a rat model of Hashimoto's thyroiditis and its mechanism of action.Experimental and therapeutic medicine · 2020Article
- Visfatin level in children and adolescents with autoimmune thyroiditis.Therapeutic advances in endocrinology and metabolism · 2017Article
- Nicotinamide phosphoribosyltransferase leukocyte overexpression in Graves' opthalmopathy.Endocrine · 2016Article
- Histopathologic Evaluation of Nonalcoholic Fatty Liver Disease in Hypothyroidism-Induced Rats.International journal of endocrinology · 2016Article
- Circulating Visfatin in Hypothyroidism Is Associated with Free Thyroid Hormones and Antithyroperoxidase Antibodies.International journal of endocrinology · 2016Article
- Adipocytokines in thyroid dysfunction.ISRN inflammation · 2013Review
- Association between novel adipocytokines adiponectin, vaspin, visfatin, and thyroid: An experimental and clinical update.Endocrine connections · 2013Article
- Alterations in serum concentrations of visfatin and betatrophin in dogs with hypothyroidism.Journal of veterinary internal medicineArticle
- The potential influence of hyperthyroidism on circulating adipokines chemerin, visfatin, and omentin.International journal of health sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alterations in thyroid function are associated with changes in body weight, metabolism, and low-grade inflammation. In several studies, plasma levels of visfatin were found to be associated with body mass index, diabetes, and metabolic syndrome. In our study we aimed to evaluate visfatin levels according to thyroid dysfunction. The study cohort comprised 56 Hashimoto thyroiditis patients with hypothyroidism (43.94+/-14.27 yr), 56 Graves patients with hyperthyroidism (45.87+/-13.28 yr), and 56 euthyroid healthy subjects (45.23+/-7.11 yr) as a control group. In addition, we evaluated the effect of therapy on plasma visfatin levels in 16 hypothyroid and in 25 hyperthyroid patients. Markedly low visfatin levels were found in hyperthyroid patients [9.44 (8.07- 10.8) ng/ml] compared with the hypothyroid [49.93 (40.72- 59.1) ng/ml] and control groups [38.6 (30.6-46.6) ng/ml] (p<0.001, p<0.001). Plasma visfatin levels in patients with hypothyroidism decreased significantly following treatment [58.58 (10.21-190.7) ng/ml vs 40.00 (10.01-102.6) ng/ml; p=0.001]. Plasma visfatin levels increased significantly after antithyroid therapy in patients with hyperthyroidism [7.86 (1.02-19.23) ng/ml vs 12.63 (3.48-110.9) ng/ml; p<0.001]. There were negative correlations between visfatin levels with free T3 (r=-0.719, p<0.001), and free T4 (r=-0.716, p<0.001) levels. There was a positive correlation between visfatin and TSH levels (r=0.701, p<0.001). There was a negative correlation between delta visfatin levels with delta free T3, delta free T4 (r=-0.686, p<0.001; r=-0.624, p<0.001). Visfatin thus seems to be regulated by thyroid hormones. While the influence of thyroid dysfunction on adipocytokine production and release is still poorly understood, the results of our study suggest that the effects of hyper- and hypothyroidism on various metabolic parameters may be partly mediated by visfatin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.